Assembly Biosciences Inc (ASMB) - Total Liabilities
Based on the latest financial reports, Assembly Biosciences Inc (ASMB) has total liabilities worth $36.90 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Assembly Biosciences Inc - Total Liabilities Trend (2008–2025)
This chart illustrates how Assembly Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. See ASMB working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Assembly Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Assembly Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alltek Technology Corp
TW:3209
|
Taiwan | NT$17.26 Billion |
|
Zhejiang Dibay Electric Co Ltd
SHG:603320
|
China | CN¥276.73 Million |
|
Fine Semitech Corp
KQ:036810
|
Korea | ₩287.68 Billion |
|
EUROKAI GmbH & Co. KGaA
F:EUK3
|
Germany | €317.79 Million |
|
Qingdao Vland Biotech Co Ltd
SHG:603739
|
China | CN¥1.14 Billion |
|
International Money Express Inc
NASDAQ:IMXI
|
USA | $261.42 Million |
|
Brainsway Ltd
TA:BWAY
|
Israel | ILA43.00 Million |
|
Sandhar Technologies Limited
NSE:SANDHAR
|
India | Rs20.99 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down Assembly Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Assembly Biosciences Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Assembly Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Assembly Biosciences Inc (2008–2025)
The table below shows the annual total liabilities of Assembly Biosciences Inc from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $50.84 Million | -40.75% |
| 2024-12-31 | $85.81 Million | -10.36% |
| 2023-12-31 | $95.73 Million | +400.40% |
| 2022-12-31 | $19.13 Million | -13.56% |
| 2021-12-31 | $22.13 Million | -48.14% |
| 2020-12-31 | $42.68 Million | -42.85% |
| 2019-12-31 | $74.67 Million | +30.10% |
| 2018-12-31 | $57.39 Million | +2.15% |
| 2017-12-31 | $56.18 Million | +208.01% |
| 2016-12-31 | $18.24 Million | +21.58% |
| 2015-12-31 | $15.00 Million | +18.56% |
| 2014-12-31 | $12.65 Million | +379.67% |
| 2013-12-31 | $2.64 Million | -3.91% |
| 2012-12-31 | $2.75 Million | +9.25% |
| 2011-12-31 | $2.51 Million | -15.96% |
| 2010-12-31 | $2.99 Million | -77.90% |
| 2009-12-31 | $13.53 Million | +31.00% |
| 2008-12-31 | $10.33 Million | -- |
About Assembly Biosciences Inc
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase … Read more